A framework for a personalized surgical approach to ovarian cancer

Nature Reviews Clinical Oncology

Volumn 12, Issue 4, 2015, Pages 239-245

  Nick, Alpa M ^a   Coleman, Robert L ^a   Ramirez, Pedro T ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; HEALTH CARE QUALITY; HUMAN; MEDICAL PRACTICE; MINIMALLY INVASIVE SURGERY; OVARIECTOMY; OVARY CANCER; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARDIZATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ALGORITHM; FEMALE; MINIMAL RESIDUAL DISEASE; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; STANDARDS;

ALGORITHMS; CHEMOTHERAPY, ADJUVANT; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HUMANS; MINIMALLY INVASIVE SURGICAL PROCEDURES; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PRECISION MEDICINE;

EID: 84925940428     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.26     Document Type: Review

References (56)

1. Elattar, A., Bryant, A., Winter-Roach, B. A., Hatem, M. & Naik, R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews, Issue 8. Art. No.: CD007565 http://dx.doi.org/10.1002/14651858.CD007565.pub2 (2011).
2. Griffiths, C. T. & Fuller, A. F. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg. Clin. North Am. 58, 131-142 (1978).
3. Eisenkop, S. M. et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol. Oncol. 90, 390-396 (2003).
4. Eisenkop, S. M., Friedman, R. L. & Wang, H. J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69, 103-108 (1998).
5. Chi, D. S. et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol. 103, 559-564 (2006).
6. Aletti, G. D. et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol. 107, 77-85 (2006).
7. Dubois, N., Willems, T. & Myant, N. Ovarian metastasis of breast cancer: a case report. Role of cytoreductive surgery [French]. J. Gynecol. Obstet. Biol. Reprod. (Paris) 38, 242-245 (2009).
8. Alberts, D. S. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950-1955 (1996).
9. Hoskins, P. J., McMurtrie, E. & Swenerton, K. D. A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity. Int. J. Gynecol. Cancer 2, 35-40 (1992).
10. Hoskins, W. J. et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170, 974-979 (1994).
11. Bristow, R. E. Tomacruz, R. S., Armstrong, D. K., Trimble, E. L. & Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-Analysis. J. Clin. Oncol. 20, 1248-1259 (2002).
12. Chi, D. S. et al. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J. Clin. Oncol. 25, 4946-4951 (2007).
13. Kang, S. et al. Frequent use of complex surgeries and survival outcomes in ovarian cancer: a propensity score analysis from the Korean Gynecologic Oncology Group [abstract]. J. Clin. Oncol. 32 (Suppl.), a5537 (2014).
14. Chi, D. S. et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 114, 26-31 (2009).
15. Winter, W. E. 3rd et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 26, 83-89 (2008).
16. du Bois, A. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe dInvestigateurs Nationaux Pour les Etudes des Cancers de lOvaire (GINECO). Cancer 115, 1234-1244 (2009).
17. Tangjitgamol, S., Manusirivithaya, S., Laopaiboon, M. & Lumbiganon, P. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD006014 http://dx.doi.org/10.1002/14651858.CD006014.pub4 (2009).
18. Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943-953 (2010).
19. Kehoe, S. et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial [abstract]. J. Clin. Oncol. 31 (Suppl.), a5500 (2013).
20. Chi, D. S. et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol. Oncol. 124, 10-14 (2012).
21. Chen, L., Learman, L. A., Weinberg, V. & Powell, C. B. Discordance between beliefs and recommendations of gynecologic oncologists in ovarian cancer management. Int. J. Gynecol. Cancer 14, 1055-1062 (2004).
22. Dewdney, S. B. et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol. Oncol. 119, 18-21 (2010).
23. Badgwell, D. & Bast, R. C. Jr. Early detection of ovarian cancer. Dis. Markers 23, 397-410 (2007).
24. Chi, D. S., Venkatraman, E. S., Masson, V. & Hoskins, W. J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol. Oncol. 77, 227-231 (2000).
25. Vorgias, G. et al. Can the preoperative CA-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol. Oncol. 112, 11-15 (2009).
26. Memarzadeh, S., Lee, S. B., Berek, J. S. & Farias-Eisner, R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer 13, 120-124 (2003).
27. Arits, A. H., Stoot, J. E., Botterweck, A. A., Roumen, F. J. & Voogd, A. C. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int. J. Gynecol. Cancer 18, 621-628 (2008).
28. Gilani, M. M. et al. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecol. Oncol. 105, 780-783 (2007).
29. Barlow, T. S., Przybylski, M., Schilder, J. M., Moore, D. H. & Look, K. Y. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int. J. Gynecol. Cancer 16, 496-500 (2006)
30. Everett, E. N. et al. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. Am. J. Obstet. Gynecol. 193, 568-574 (2005).
31. Brockbank, E. C. et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int. J. Gynecol. Cancer 14, 42-50 (2004).
32. Rossi, A. C. et al. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer. Arch. Gynecol. Obstet. 269, 263-265 (2004).
33. Obeidat, B., Latimer, J. & Crawford, R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol. Obstet. Invest. 57, 153-156 (2004).
34. Alcazar, J. L. et al. CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma. Int. J. Gynaecol. Obstet. 84, 173-174 (2004).
35. Cooper, B. C. et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet. Gynecol. 100, 59-64 (2002).
36. Saygili, U. et al. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol. Oncol. 86, 57-61 (2002).
37. Gemer, O., Segal, S. & Kopmar, A. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet. Gynecol. Scand. 80, 583-585 (2001).
38. Nelson, B. E., Rosenfield, A. T. & Schwartz, P. E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J. Clin. Oncol. 11, 166-172 (1993).
39. Meyer, J. I., Kennedy, A. W., Friedman, R., Ayoub, A. & Zepp, R. C. Ovarian carcinoma: value of CT in predicting success of debulking surgery. AJR Am. J. Roentgenol. 165, 875-878 (1995).
40. Dowdy, S. C., Mullany, S. A., Brandt, K. R., Huppert, B. J. & Cliby, W. A. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 101, 346-352 (2004).
41. Bristow, R. E. et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89, 1532-1540 (2000).
42. Axtell, A. E. et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol. 25, 384-389 (2007).
43. Byrom, J. Widjaja, E., Redman, C. W., Jones, P. W. & Tebby, S. Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy? BJOG 109, 369-375 (2002).
44. Suidan, R. S. et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol. Oncol. 134, 455-461 (2014).
45. Abdallah, R., Chon, H. S. & Gonzalez Bosquet, J. Gene expression and prediction of complete cytoreduction in ovarian cancer. Obstet. Gynecol. 123 (Suppl. 1), 89S (2014).
46. Tucker, S. L. et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin. Cancer Res. 20, 3280-3288 (2014).
47. Chi, D. S. et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol. Oncol. 112, 6-10 (2009).
48. Eltabbakh, G. H. et al. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol. Oncol. 95, 377-383 (2004).
49. Gemer, O. et al. A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur. J. Surg. Oncol. 31, 1006-1010 (2005).
50. Fagotti, A. et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol. Oncol. 96, 729-735 (2005).
51. Fagotti, A. et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann. Surg. Oncol. 13, 1156-1161 (2006).
52. Fagotti, A. et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am. J. Obstet. Gynecol. 199, 642.e1-e6 (2008).
53. Fagotti, A. et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol. Oncol. 131, 341-346 (2013).
54. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01461850?term=NCT01461850 & rank=1 (2013).
55. The University of Texas MD Anderson Cancer Center. The Moon Shots Program [online], http://www.cancermoonshots.org (2014).
56. Nick, A. M. Personalized surgical therapy for advanced ovarian cancer. Presented at the 50th American Society of Gynecologic Oncology Annual Meeting (2014).